Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Alimta ® (pemetrexed for injection)
Alimta® (pemetrexed): Vitamin Supplementation
Prior to pemetrexed treatment, initiate vitamin supplementation consisting of oral folic acid and IM vitamin B12 to reduce severity of pemetrexed toxicity.
To reduce toxicity, patients treated with pemetrexed must be instructed to take a folic acid preparation or a multivitamin with folic acid
- as a daily oral low-dose
- initiated during the 7-day period preceding the first dose of pemetrexed, and for at least 5 doses, and
- during the full course of therapy and for 21 days after the last dose of pemetrexed.1
In clinical trials, the dose of folic acid studied ranged from 350 to 1000 μg. The most commonly used dose of oral folic acid in clinical trials was 400 μg.2
Effects of Vitamin Supplementation on Toxicity
In the phase 3 malignant pleural mesothelioma (MPM) registration trial, pretreatment with folic acid and vitamin B12 led to overall less toxicity and reduction in grade 3/4 hematologic and nonhematologic toxicities such as
Therefore, patients treated with pemetrexed must be instructed to take folic acid and vitamin B12 as a prophylactic measure to reduce treatment-related toxicity.2
Effects of Vitamin Supplementation on Pharmacokinetics
The pharmacokinetics (PK) of pemetrexed is not influenced by oral folic acid and IM vitamin B12 supplementation.2
1Alimta [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. https://doi.org/10.1200/JCO.2003.11.136
Date of Last Review: May 27, 2021